The Future We're Creating
TRIDENT™ envisions a future in which cancer treatment is characterized by therapeutic precision rather than acceptable toxicity—achieved through multiple therapeutic pathways that address the full spectrum of oncology challenges. Patients receive precisely the therapy their specific cancer needs, delivered exactly where and when it can be most effective, with the assurance that healthy tissue remains protected.
Mission
The Four Pillars of Precision Delivery
Our Mission: Redefining What's Possible
The TRIDENT™ platform has the potential to revolutionize this fundamental equation by addressing not only how drugs are delivered but also what can be accomplished when delivery is perfected. Our goal is not simply to enhance existing therapies, but to unlock therapeutic potential that was previously inaccessible through two groundbreaking therapeutic strategies that utilize our precision delivery technology.
Transforming Systemic Harm into Localized Healing
What We Achieve: Therapeutic precision that distinguishes between malignant and healthy tissue at the cellular level.
Traditional chemotherapy treats the entire body to reach the tumor. TRIDENT™ is designed to reverse this paradigm, delivering therapeutic payloads exclusively where cancer resides while sparing healthy tissue from unnecessary assault. This selectivity doesn't merely reduce side effects—it fundamentally redefines the therapeutic window.
The Transformation: From systemic toxicity management to localized therapeutic activation.
Eliminating the Choice Between Efficacy and Safety
What We Achieve: Liberation from dose-limiting toxicities that have constrained cancer treatment for generations.
Current therapeutic protocols force impossible choices: aggressive treatment with severe consequences or conservative dosing with compromised outcomes. TRIDENT™ is designed to eliminate this dilemma by creating a protective barrier between therapeutic agents and vulnerable organs, especially the heart, liver, and kidneys.
The Transformation: From toxicity-limited dosing to efficacy-optimized treatment.
Mastering the When and Where of Therapeutic Action
What We Achieve: Temporal and spatial control over drug activation, ensuring therapy occurs precisely when and where it can be most effective.
Conventional drug delivery depends on hope—hoping sufficient drug reaches the tumor before systemic clearance or degradation occurs. TRIDENT™ replaces hope with control, using tumor-specific environmental cues to trigger drug release precisely when therapeutic conditions are optimal.
The Transformation: From passive drug distribution to active therapeutic orchestration.
Enabling the Long-Term War Against Cancer
What We Achieve: Treatment regimens that patients can tolerate across multiple cycles, enabling sustained therapeutic pressure against cancer.
Cancer treatment often becomes a race against time—will the therapy eliminate the cancer before cumulative toxicity necessitates ceasing treatment? TRIDENT™ transforms this dynamic by establishing sustainable treatment platforms that preserve therapeutic intensity without causing systemic damage to accumulate.
The Transformation: From limited treatment windows to sustained therapeutic campaigns.
Challenge in Oncology
The Fundamental Challenge in Oncology
Cancer treatment has long been hindered by a paradox: the most effective therapies often cause the most harm. For decades, oncologists have needed to balance therapeutic potential against toxicity limitations, frequently settling for suboptimal outcomes to ensure patient safety. This compromise has defined the boundaries of what is achievable in cancer care.
The Ripple Effect
Research Renaissance:
Previously overlooked compounds re-enter development pipelines as new targets become accessible.
Clinical Revolution:
Trial designs prioritize optimizing efficacy across both pathway approaches rather than focusing on toxicity management.
Patient Empowerment:
Treatment emphasizes healing through precise delivery, whether targeting broadly or specifically.
Healthcare Evolution:
Resources are transitioning from managing toxicity to pursuing cures through diverse therapeutic modalities.
Proposition
The TRIDENT™ Proposition
Every cancer therapeutic has an optimal efficacy profile. Most are never allowed to achieve it due to delivery limitations. TRIDENT™ is designed to eliminates those limitations across multiple therapeutic pathways, unlocking the full potential that has always existed within both established cancer treatments and next-generation precision therapeutics.
Primary Focus
Targeted Chemotherapy
-
Expedited development timelines using a 505(b)(2) regulatory strategy
-
Reduce development costs by utilizing existing safety data
-
Significant addressable markets with proven clinical evidence
-
Partnership opportunities with generic manufacturers looking for differentiation
Secondary Focus
Nanobody - Drug - Conjugates
-
Access to new targets and specialized indications
-
Increased pricing potential for precision-targeted therapies
-
Patent protection that goes beyond traditional small molecules
-
Platform scalability for various cancer-specific antigens